FDA issues complete response letter on Outlook Therapeutics (OTLK) ONS-5010 wet AMD filing

Rhea-AI Filing Summary

Outlook Therapeutics, Inc. reported that the U.S. Food and Drug Administration issued a complete response letter to its biologics license application for ONS-5010, an investigational ophthalmic formulation of bevacizumab being developed to treat wet age-related macular degeneration (wet AMD). A complete response letter means the FDA has finished its review but has decided that the application cannot be approved in its current form. The company disclosed this development through a press release, which is included as an exhibit to the report.

Positive

• None.

Negative

• FDA complete response letter for ONS-5010 BLA indicates the biologics license application for the company’s investigational wet AMD therapy is not approvable in its current form, representing a material regulatory setback.

Insights

Biopharma regulatory analyst

FDA complete response letter delays ONS-5010 path for wet AMD.

The company states that the FDA has issued a complete response letter to the biologics license application for ONS-5010, an ophthalmic bevacizumab product candidate for wet AMD. A complete response letter indicates the review cycle is complete but the current application is not approvable as submitted.

This development is significant because ONS-5010 is described as an investigational therapy, so regulatory feedback directly affects its potential path toward commercialization. The specific issues and next steps are not detailed here and instead are referenced in the attached press release, meaning further context would come from that exhibit.

The timing and feasibility of any resubmission would likely depend on the contents of the complete response letter, but those details are not provided in this excerpt. Subsequent company communications and filings would be expected to outline how the company responds to the FDA’s feedback.

false 0001649989 0001649989 2025-08-28 2025-08-28 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 28, 2025

Outlook Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware	001-37759	38-3982704
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

111 S. Wood Avenue, Unit #100 Iselin, New Jersey	08830
(Address of principal executive offices)	(Zip Code)

Registrant's telephone number, including area code: (609) 619-3990

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities pursuant to Section 12 (b) of the Act:

Title of Each Class		Trading Symbol(s)		Name of Each Exchange on Which Registered
Common Stock		OTLK		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 8.01 Other Events.

On August 28, 2025, Outlook Therapeutics, Inc (the “Company”) issued a press release announcing that the U.S. Food and Drug Administration issued a complete response letter to the Company’s biologics license application for ONS-5010, an investigational ophthalmic formulation of bevacizumab under development to treat wet AMD.

The press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated into this item 8.01 by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release, dated August 28, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Outlook Therapeutics, Inc.
Date: September 2, 2025	By:	/s/ Lawrence A. Kenyon
		Lawrence A. Kenyon
		Chief Financial Officer

FAQ

What did Outlook Therapeutics (OTLK) announce in this 8-K?

Outlook Therapeutics announced that the U.S. Food and Drug Administration issued a complete response letter to its biologics license application for ONS-5010, an investigational treatment for wet AMD.

What is ONS-5010 that Outlook Therapeutics is developing?

ONS-5010 is described as an investigational ophthalmic formulation of bevacizumab that Outlook Therapeutics is developing to treat wet age-related macular degeneration (wet AMD).

What does an FDA complete response letter mean for Outlook Therapeutics?

A complete response letter means the FDA has completed its review of the application but determined that it cannot approve it in its current form. The filing does not provide further detail beyond referencing the company’s press release.

Where can investors find more detail on the FDA’s letter to Outlook Therapeutics?

Additional detail is provided in the company’s press release dated August 28, 2025, which is attached as Exhibit 99.1 to the report and incorporated by reference.

Which product area of Outlook Therapeutics is affected by this FDA decision?

The FDA’s complete response letter affects Outlook Therapeutics’ ophthalmology program, specifically the biologics license application for ONS-5010 for treating wet AMD.